BiotechTube

NNZ-2566 + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome

Trial Timeline

Mar 1, 2016 → Jan 5, 2017

NCT ID
NCT02715115

About NNZ-2566 + Placebo

NNZ-2566 + Placebo is a phase 2 stage product being developed by Neuren Pharmaceuticals for Rett Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02715115. Target conditions include Rett Syndrome.

What happened to similar drugs?

3 of 9 similar drugs in Rett Syndrome were approved

Approved (3) Terminated (3) Active (3)
✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
✅Esomeprazole + LansoprazoleAstraZenecaApproved
✅Esomeprazole MagnesiumAstraZenecaApproved
❌GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
❌GWP42003-PJazz PharmaceuticalsPhase 3
❌trofinetideAcadia PharmaceuticalsPhase 3
🔄TrofinetideAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT02715115Phase 2Completed
NCT02100150Phase 2Terminated
NCT01894958Phase 2Completed
NCT01703533Phase 2Completed
NCT01366820Phase 2Completed
NCT01420042Phase 1Completed
NCT00805818Phase 2Completed
NCT00961779Phase 1Completed

Competing Products

20 competing products in Rett Syndrome

See all competitors
ProductCompanyStageHype Score
Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
43
Esomeprazole + LansoprazoleAstraZenecaApproved
43
Esomeprazole MagnesiumAstraZenecaApproved
43
AZD5213 and placeboAstraZenecaPhase 2
35
fingolimod (FTY720)NovartisPhase 1/2
32
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
27
AripiprazoleBristol Myers SquibbPre-clinical
18
NBI-98854Neurocrine BiosciencesPhase 2
24
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
24
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854Neurocrine BiosciencesPhase 1
26
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
32
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
32
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
32
Abobotulinum toxin AIpsenPre-clinical
19
GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
29
GWP42003-PJazz PharmaceuticalsPhase 3
29
trofinetideAcadia PharmaceuticalsPhase 3
29
TrofinetideAcadia PharmaceuticalsPhase 3
37